Inventor · disambiguated record
Jan Henrik Ter Meulen
Also filed as: TER MEULEN JAN · TER MEULEN JAN H · TER MEULEN JAN HENRIK
11 granted patents·15 pending applications·83 citations·filing 2005–2023
88Inventor score
Files withIMMUNE DESIGN CORP12OBSIDIAN THERAPEUTICS INC5CRUCELL HOLLAND BV4MERCK SHARP & DOHME2PEDRO KYLE1
Top patents by PatentIndex Score
26 records- 0193US8106170B2Compositions against SARS-coronavirus and uses thereofTER MEULEN JAN HENRIK·Filed 2005·Granted Jan 31, 2012·48 cites·11 claims
- 0290US11406706B2Lipid nanoparticle vaccine adjuvants and antigen delivery systemsMERCK SHARP & DOHME·Filed 2020·Granted Aug 9, 2022·2 cites·18 claims
- 0390US10821175B2Lipid nanoparticle vaccine adjuvants and antigen delivery systemsMERCK SHARP & DOHME·Filed 2015·Granted Nov 3, 2020·5 cites·12 claims
- 0488US7888102B2Cell line for producing coronavirusesCRUCELL HOLLAND BV·Filed 2006·Granted Feb 15, 2011·9 cites·12 claims
- 0587US8957047B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2014·Granted Feb 17, 2015·12 cites·40 claims
- 0680US8962593B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2014·Granted Feb 24, 2015·4 cites·18 claims
- 0776US10584356B2Multigenome retroviral vector preparations and methods and systems for producing and using sameIMMUNE DESIGN CORP·Filed 2018·Granted Mar 10, 2020·2 cites·25 claims
- 0872US10993956B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2019·Granted May 4, 2021·0 cites·11 claims
- 0970US11365230B2Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereofIMMUNE DESIGN CORP·Filed 2016·Granted Jun 21, 2022·1 cites·11 claims
- 1070US2024226158A9Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancerOBSIDIAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1163US2022133801A1Administration of tumor infiltrating lymphocytes with membrane bound interleukin 15 to treat cancerOBSIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1261US2010172917A1Binding molecules against SARS-coronavirus and uses thereofCRUCELL HOLLAND BV·Filed 2009·Application pending·0 cites
- 1360US2024424136A1Compositions and systems for regulation of function/abundance and delivery of polypeptide payloadsOBSIDIAN THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1460US2024108722A1Tumor-infiltrating lymphocytes with membrane bound interleukin 15 and uses thereofPEDRO KYLE·Filed 2022·Application pending·0 cites
- 1559US2025186614A1Compact drug responsive domains for regulation of function/abundance and delivery of polypeptide payloadsOBSIDIAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1655US2025134928A1Methods for identifying and using allogeneic tumor infiltrating lymphocytes to treat cancerOBSIDIAN THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1754US10342815B2GLA monotherapy for use in cancer treatmentIMMUNE DESIGN CORP·Filed 2015·Granted Jul 9, 2019·0 cites·17 claims
- 1849US2015352135A1GLA Monotherapy for Use in Cancer TreatmentIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 1949US2006154243A1Antigenic peptides of SARS coronavirus and uses thereofTER MEULEN JAN·Filed 2006·Application pending·0 cites
- 2047US2022054611A1Pathogen-associated molecular pattern molecules and rna immunogenic compositions and methods of using the compositions for treating cancerIMMUNE DESIGN CORP·Filed 2019·Application pending·0 cites
- 2145US10179919B2Multigenome retroviral vector preparations and methods and systems for producing and using sameIMMUNE DESIGN CORP·Filed 2017·Granted Jan 15, 2019·0 cites·47 claims
- 2243US2007128217A1Antigenic peptides of SARS coronavirus and uses thereofCRUCELL HOLLAND BV·Filed 2006·Application pending·0 cites
- 2341US2006110803A1Antigenic peptides of SARS coronavirus and uses thereofCRUCELL HOLLAND BV·Filed 2005·Application pending·0 cites
- 2437US2019119350A1Ny-eso-1 specific tcrs and methods of use thereofIMMUNE DESIGN CORP·Filed 2016·Application pending·0 cites
- 2537US2017196954A1Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vectorIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
- 2630US2016058852A1Immunotherapy of cancer through combination of local and systemic immune stimulationIMMUNE DESIGN CORP·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jan Henrik Ter Meulen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →